A high ratio of IC31^® adjuvant to antigen is necessary for H4 TB vaccine immunomodulation

References

• van Dissel JT, Soonawala D, Joosten SA, Prins C, Arend SM, Bang P, Tingskov PN, Lingnau K, Nouta J, Hoff ST, et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 2011; 29:2100-9; PMID:21256189; http://dx.doi.org/10.1016/j.vaccine.2010.12.135
   PubMed Web of Science ®Google Scholar
• Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, Phan T, Orme IM, Vedvick TS, Baldwin SL, et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2010; 2:53-74; PMID:20944089; http://dx.doi.org/10.1126/scitranslmed.3001094
   PubMedGoogle Scholar
• Lin PL, Dietrich J, Tan E, Abalos RM, Burgos J, Bigbee C, Bigbee M, Milk L, Gideon HP, Rodgers M, et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 2012; 122:303-14; PMID:22133873; http://dx.doi.org/10.1172/JCI46252
   PubMed Web of Science ®Google Scholar
• Day CL, Tameris M, Mansoor N, van Rooyen M, de Kock M, Geldenhuys H, Erasmus M, Makhethe L, Hughes EJ, Gelderbloem S, et al. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am J Respir Crit Care Med 2013; 188:492-502; PMID:23306546; http://dx.doi.org/10.1164/rccm.201208-1385OC
   PubMed Web of Science ®Google Scholar
• Billeskov R, Elvang TT, Andersen PL, Dietrich J: The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One 2012; 7: e39909; PMID:22768165; http://dx.doi.org/10.1371/journal.pone.0039909
   PubMed Web of Science ®Google Scholar
• Aichinger MC, Ginzler M, Weghuber J, Zimmermann L, Riedl K, Schutz G, Nagy E, von Gabain A, Schweyen R, Henics T. Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells. Vaccine 2011; 29:426-36; PMID:21093498; http://dx.doi.org/10.1016/j.vaccine.2010.11.003
   PubMed Web of Science ®Google Scholar
• Szabo A, Gogolak P, Pazmandi K, Kis-Toth K, Riedl K, Wizel B, Lingnau K, Bacsi A, Rethi B, Rajnavolgyi E. The two-component adjuvant IC31 boosts type I interferon production of human monocyte-derived dendritic cells via ligation of endosomal TLRs. PLoS One 2013; 8: e55264; PMID:23405128; http://dx.doi.org/10.1371/journal.pone.0055264
   PubMed Web of Science ®Google Scholar
• Skeiky YAW, Dietrich J, Lasco TM, Stagliano K, Dheenadhayalan V, Goetz MA, Cantarero L, Basaraba RJ, Bang P, Kromann I, et al. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine 2010; 28:1084-93; PMID:19896449; http://dx.doi.org/10.1016/j.vaccine.2009.10.114
   PubMed Web of Science ®Google Scholar
• Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, Doherty TM, Andersen P. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J. Immunol 2005; 174:6332-9; PMID:15879133; http://dx.doi.org/10.4049/jimmunol.174.10.6332
   PubMed Web of Science ®Google Scholar
• Kamath AT, Valenti MP, Rochat AF, Agger EM, Lingnau K, von Gabain A, Andersen P, Lambert PH, Siegrist CA. Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells. Eur J Immunol 2008; 38:1247-56; PMID:18412160; http://dx.doi.org/10.1002/eji.200737889
   PubMedGoogle Scholar
• Kamath AT, Rochat AF, Valenti MP, Agger EM, Lingnau K, Andersen P, Lambert PH, Siegrist CA. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. PLoS One 2008; 3:e3683; PMID:18997860; http://dx.doi.org/10.1371/journal.pone.0003683
   PubMedGoogle Scholar
• Aagaard C, Hoang TTKT, Izzo A, Billeskov R, Troudt J, Arnett K, Keyser A, Elvang T, Andersen P, Dietrich J. Protection and polyfunctional T cells induced by Ag85B- TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS One 2009; 4: e5930; PMID:19529771; http://dx.doi.org/10.1371/journal.pone.0005930
   PubMed Web of Science ®Google Scholar
• van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, Lingnau K, Nouta J, Klein MR, Rosenkrands I, Ottenhoff TH, et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010; 28:3571-81; PMID:20226890; http://dx.doi.org/10.1016/j.vaccine.2010.02.094
   PubMed Web of Science ®Google Scholar
• Brookes RH, Hakimi J, Ha Y, Aboutorabian S, Ausar SF, Hasija M, Smith SG, Todry SM, Dockrell HM, Rahman N. Screening vaccine formulations for biological activity using fresh human whole blood. Hum Vaccines Immunother 2014; 10:0-1; PMID:24401565; http://dx.doi.org/10.4161/hv.27657
   PubMedGoogle Scholar
• Germain RN. Vaccines and the future of human immunology. Immunity 2010; 33:441-50; PMID:21029956; http://dx.doi.org/10.1016/j.immuni.2010.09.014
   PubMed Web of Science ®Google Scholar
• Duthie MS, Windish HP, Fox CB, Reed SG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011; 239:178-96; PMID:21198672; http://dx.doi.org/10.1111/j.1600-065X.2010.00978.x
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183:6186-97; PMID:19864596; http://dx.doi.org/10.4049/jimmunol.0901474
   PubMed Web of Science ®Google Scholar
• Brito LA, O'Hagan DT. Designing and building the next generation of improved vaccine adjuvants. J Control Release 2014; 190:563-79; PMID:24998942; http://dx.doi.org/10.1016/j.jconrel.2014.06.027
   PubMed Web of Science ®Google Scholar
• Chen X, Liu Y, Wang L, Liu Y, Zhang W, Fan B, Ma X, Yuan Q, Ma G, Su Z. Enhanced humoral and cell-mediated immune responses generated by cationic polymer-coated PLA microspheres with adsorbed HBsAg. Mol Pharmaceutics 2014; 11:1772-84; PMID:24738485; http://dx.doi.org/10.1021/mp400597z
   PubMedGoogle Scholar
• Davey MS, Morgan MP, Liuzzi AR, Tyler CJ, Khan MWA, Szakmany T, Hall JE, Moser B, Eberl M. Microbe-specific unconventional T cells induce human neutrophil differentiation into antigen cross-presenting cells. J Immunol 2014; 193:3704-16; PMID:25165152; http://dx.doi.org/10.4049/jimmunol.1401018
   PubMedGoogle Scholar
• Kamath AT, Mastelic B, Christensen D, Rochat AF, Agger EM, Pinschewer DD, Andersen P, Lambert PH, Siegrist CA. Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses. J Immunol 2012; 188:4828-37; PMID:22504654; http://dx.doi.org/10.4049/jimmunol.1103183
   PubMed Web of Science ®Google Scholar